Literature DB >> 15280458

Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner.

J A McKeating1, L Q Zhang, C Logvinoff, M Flint, J Zhang, J Yu, D Butera, D D Ho, L B Dustin, C M Rice, P Balfe.   

Abstract

We recently reported that retroviral pseudotypes bearing the hepatitis C virus (HCV) strain H and Con1 glycoproteins, genotype 1a and 1b, respectively, require CD81 as a coreceptor for virus-cell entry and infection. Soluble truncated E2 cloned from a number of diverse HCV genotypes fail to interact with CD81, suggesting that viruses of diverse origin may utilize different receptors and display altered cell tropism. We have used the pseudotyping system to study the tropism of viruses bearing diverse HCV glycoproteins. Viruses bearing these glycoproteins showed a 150-fold range in infectivity for hepatoma cells and failed to infect lymphoid cells. The level of glycoprotein incorporation into particles varied considerably between strains, generally reflecting the E2 expression level within transfected cells. However, differences in glycoprotein incorporation were not associated with virus infectivity, suggesting that infectivity is not limited by the absolute level of glycoprotein. All HCV pseudotypes failed to infect HepG2 cells and yet infected the same cells after transduction to express human CD81, confirming the critical role of CD81 in HCV infection. Interestingly, these HCV pseudotypes differed in their ability to infect HepG2 cells expressing a panel of CD81 variants, suggesting subtle differences in the interaction of CD81 residues with diverse viral glycoproteins. Our current model of HCV infection suggests that CD81, together with additional unknown liver specific receptor(s), mediate the virus-cell entry process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280458      PMCID: PMC479078          DOI: 10.1128/JVI.78.16.8496-8505.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

2.  Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Authors:  F Gao; S G Morrison; D L Robertson; C L Thornton; S Craig; G Karlsson; J Sodroski; M Morgado; B Galvao-Castro; H von Briesen; S Beddows; J Weber; P M Sharp; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

4.  Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines.

Authors:  Sabine Wellnitz; Bettina Klumpp; Heidi Barth; Susumu Ito; Erik Depla; Jean Dubuisson; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment.

Authors:  Michel Lambot; Stéphanie Frétier; Anne Op De Beeck; Brigitte Quatannens; Sophie Lestavel; Veronique Clavey; Jean Dubuisson
Journal:  J Biol Chem       Date:  2002-04-05       Impact factor: 5.157

6.  Extrahepatic manifestations of hepatitis C among United States male veterans.

Authors:  Hashem B El-Serag; Howard Hampel; Christine Yeh; Linda Rabeneck
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

7.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

8.  Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.

Authors:  RosaMaria Roccasecca; Helenia Ansuini; Alessandra Vitelli; Annalisa Meola; Elisa Scarselli; Stefano Acali; Monica Pezzanera; Bruno Bruni Ercole; Jane McKeating; Asutosh Yagnik; Armin Lahm; Anna Tramontano; Riccardo Cortese; Alfredo Nicosia
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes.

Authors:  A L Erickson; Y Kimura; S Igarashi; J Eichelberger; M Houghton; J Sidney; D McKinney; A Sette; A L Hughes; C M Walker
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

10.  Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication.

Authors:  Keril J Blight; Jane A McKeating; Charles M Rice
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

View more
  70 in total

Review 1.  Tetraspanins in viral infections: a fundamental role in viral biology?

Authors:  F Martin; D M Roth; D A Jans; C W Pouton; L J Partridge; P N Monk; G W Moseley
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

2.  Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.

Authors:  Kathleen McCaffrey; Irene Boo; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

Review 3.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

4.  Hepatitis C Virus Entry into Macrophages/Monocytes Mainly Depends on the Phagocytosis of Macrophages.

Authors:  Yuan Liu; Wenbo Wang; Ziying Zou; Zonghai Hu; Quanshui Fan; Jie Xiong
Journal:  Dig Dis Sci       Date:  2018-12-10       Impact factor: 3.199

5.  A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.

Authors:  Heidi E Drummer; Irene Boo; Anne L Maerz; Pantelis Poumbourios
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Authors:  Thomas Pietschmann; Artur Kaul; George Koutsoudakis; Anna Shavinskaya; Stephanie Kallis; Eike Steinmann; Karim Abid; Francesco Negro; Marlene Dreux; Francois-Loic Cosset; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

7.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

9.  In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Authors:  Meital Gal-Tanamy; Zhen-Yong Keck; MinKyung Yi; Jane A McKeating; Arvind H Patel; Steven K H Foung; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

10.  RNA interference and single particle tracking analysis of hepatitis C virus endocytosis.

Authors:  Kelly E Coller; Kristi L Berger; Nicholas S Heaton; Jacob D Cooper; Rosa Yoon; Glenn Randall
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.